ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements with these filters
Procter & Gamble Health informed shareholders about an extended SEBI-mandated special window for re-lodging rejected physical share transfer requests until February 4, 2027.
Procter & Gamble Health shareholders approved the re-appointment of Mr. S. Madhavan as an Independent Director for a five-year term starting November 15, 2026.
Procter & Gamble Health held its 59th Annual General Meeting on September 3, 2026, where shareholders discussed financial results and directorial appointments.
Procter & Gamble Health Limited has filed its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026.
Procter & Gamble Health Ltd has rescheduled its 59th AGM to September 3, 2026. The record date for the final dividend and AGM is August 27, 2026.
Procter & Gamble Health reported a 7% increase in quarterly sales to ₹356 crore. Profit After Tax rose 45% to ₹96 crore, aided by asset sale proceeds.
Procter & Gamble Health Ltd reported revenue from operations of ₹363.7 Cr (+7.4% YoY) and net profit of ₹96.2 Cr (+45.3% YoY) for Q1 FY27.
Procter & Gamble Health Limited declared a final dividend of Rs. 45 per share for the fiscal year 2025-2026. The record date is set for August 27, 2026.
Procter & Gamble Health rescheduled its 59th AGM to September 3, 2026. The record date for final dividend is now August 27, 2026.
Procter & Gamble Health scheduled a board meeting for August 6, 2026. The meeting will consider unaudited financial results for the June quarter.
Procter & Gamble Health announced senior management changes effective July 1, 2026. Updates include role changes and the appointment of Mr. Shine Matthew Sunny.
Procter & Gamble Health Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The report notes an inadvertent delay in disclosing a director's appointment.
Procter & Gamble Health re-appointed Subramanian Madhavan as Independent Director for a five-year term. The board-approved move ensures leadership continuity through November 2031.
Procter & Gamble Health recommended a final dividend of ₹45 per equity share for FY 2025-26. The record date for payment is fixed as August 21, 2026.
Procter & Gamble Health set August 21, 2026, as the record date for dividend payment. The dividend remains subject to shareholder approval at the August AGM.
Procter & Gamble Health re-appointed Mr. S. Madhavan as Independent Director for five years starting November 2026. The move ensures leadership continuity and board stability.
Procter & Gamble Health reported FY26 sales of ₹1385 Crore and PAT of ₹327 Crore. The Board recommended a final dividend of ₹45 per share.
Procter & Gamble Health Ltd reported revenue from operations of ₹370.4 Cr (+19.1% YoY) and net profit of ₹94.6 Cr (+54.6% YoY) for Q4 FY26.
Procter & Gamble Health reported a ₹449.86 Crore profit before tax for FY2026. The board recommended a ₹45 per share dividend, reflecting strong annual performance.
Procter & Gamble Health Limited has executed a sale agreement for immovable properties in Mumbai. The transaction is expected to generate a profit of approximately ₹32 Crore for the company.